Dolly: the science behind the world's most famous sheep by Griffin, H D
DOLLY:  THE SCIENCE BEHIND THE WORLD’S MOST FAMOUS SHEEP
H.D. Griffin
Roslin Institute (Edinburgh),  Roslin,  UK
Abstract
‘The Roslin Institute near Edinburgh is one of the world’s leading centres for
research on farm animals. Its main expertise is in animal genetics, with the
results benefiting the livestock breeding and production industries in
particular.  Its work was, however, little known to the general public. A single
lamb  changed all that.  Dr Harry Griffin, Assistant Director at the Institute,
explains.....’
Dolly  was the first mammal cloned from a cell from an adult animal.  She was derived from cells that had been
taken from the udder of a 6-year old Finn Dorset ewe and cultured for several weeks in the laboratory. Individual
cells were then fused with unfertilised eggs from which the genetic material had been removed. Two hundred and
seventy seven of these ‘reconstructed eggs’ - each now with a diploid nucleus from the adult animal - were
cultured for  6 days in temporary recipients.  Twenty nine of the eggs that appeared to have developed normally
to the blastocyst stage were implanted into surrogate Scottish Blackface ewes. One gave rise to  live lamb, Dolly,
 some 148 days later.
DOLLYMANIA
Dolly was born on 5 July 1996. It took Ian Wilmut and his colleagues a few weeks to complete the experimental
work and several more months before they had written a paper and had it accepted by Nature. Publication was
confirmed for  27 February, 1997 and by then plans were well advanced to handle the expected media interest.
 We knew  that Nature was featuring Dolly in the weekly press release that it distributes each  Friday. The
information in these releases is ‘embargoed’ until 7 o’clock on the Wednesday evening before publication and
this is intended to provide journalists time to research their stories more carefully before going to press.  However,
 ideas of a relaxing weekend were shattered by  two phone calls late on Saturday  warning  us that the Observer
would be running the story the next day. 
A quick visit to the newsagents first thing on Sunday confirmed our story was on the front page.  The
Observer’s science writer Robin McKie  had resisted taking a sensational line but he had raised fears about
human cloning.   Our main aim then was to ensure that the other papers have some solid facts to report.  Two of
the team at Roslin and four at our PR agency De facto’s office in Basingstoke worked throughout the day to
answer  calls from  around the world and set up schedules for reporters,  TV crews and photographers desperate
to visit Roslin.
On Monday,  Dolly provided a major story in most of the  papers and Roslin was besieged by  reporters
and TV crews from all over the world.  ABC, NBC, CNN and CBS all beamed live interviews across the Atlantic
via satellite vans in the car park.  Phones rang incessantly and extra spokesmen were drafted in to help.  Dolly
quickly became the most photographed sheep of all time  and was invited to appear on a chat show in the US.
Astrologers asked  for her date of birth and the shares of our collaborators PPL  rose sharply.  President Bill
Clinton called on his bioethics commission to report on the ethical implications within 90 days and Ian Wilmut
was invited to testify to both the UK House of Commons and  the US Congress.  Dolly Parton said she was
‘honoured’ that we had called our sheep after her.
In the first week after the story broke, we estimated that together the Roslin Institute, PPL and De Facto
answered more than 2000 telephone calls,  talked at length to close on 100 reporters and provided access to Dolly
to 16 film crews and more than 50 photographers from all over the world. After all this, the actual publication
of the paper in Nature on Thursday 27 February seemed an anticlimax.   
‘Science Breakthrough of the Year’
For developmental biologists, Dolly’s existence challenges one of the fundamental tenets of developmental
biology.  Most scientists had thought that differentiation - the gradual process of specialisation that allows the
fertilised egg to develop into the hundreds of cell types that make up the whole animal- was irreversible. After
all, even over a 90 year lifespan a liver remains a liver, a nerve cell a nerve cell.  The production of a live lamb
from a cell taken from the udder of  a 6-year old ewe demonstrated that differentiated cells are not immutable:
it was possible to take a differentiated cell and turn its biological clock back to zero. To start its life all over again.
 And for this, Dolly was voted ‘Science Breakthrough of 1997’  by the editors of the prestigious US journal
Science, ahead of NASA’s Pathfinder mission to Mars and advances in cyclotron design.
At first Dolly was a clone alone, but in recent months clones of adult mice have been reported from Hawaii and
cloned calves from both New Zealand and Japan. These additional reports demonstrate that Dolly is not an
‘anecdote’ and that it should be possible to clone from a variety of different cell types and species.
Cloning of humans
The intense media interest was not with sheep.  The immediate assumption was that cloning of humans was just
around the corner and that seemed to trigger an explosion (at least in the media) of  fears about the future. 
However, in contrast to the barrage of calls from the press, the relatively small size of our postbag suggested that
the general public was  much more sanguine.  They seemed to know that the scenarios that the media were
imagining were unlikely to be realised and could, as a consequence, be enjoyed in safety. Just like ‘the X  files’.
Much of the media speculation was based on science fiction rather than good sense,  with the Times and
a Dr Patrick Dixon taking our  award for the most outrageous list of  ‘reasons’ for cloning humans.  A common
misunderstanding was that clones would be somehow less than human.   However, most of us have already met
a human clone - an identical twin - and no one would seriously suggest that we should produce twins to order as
sources of spare parts. Others seemed to believe that cloning would produce an identical photocopy, rather than
a child that would grow up with a personality and behaviour all of its own.
Those speculating about potential uses in humans need to recognise that the technology is very much in
its infancy.  Our experiments in sheep produced several lambs with developmental abnormalities that died in late
pregnancy or soon after being born.  A clone will inherit somatic mutations from the donor and this in turn may
lead to premature ageing or a higher incidence of cancer later in life.  These risks alone mean that it would be
grossly unethical to perform similar experiments in women now, however desperate they might be to have a child.
Experience with cloning in farm animals may identify ways of reducing risk  but this is likely to take
many years.  In the meantime,  society as a whole has time to contemplate which uses of the technology might
be acceptable and which would not.  Views will inevitable change over time: the first test tube baby, Louise
Brown, was born in 1979 and in vitro fertilisation is now commonplace.  Attitudes will also vary between
countries: many feared cloning would be exploited by megalomaniacs but in our view it is far more likely that
the ethical boundaries will be tested by the in vitro fertilisation clinics in the US or the Far East.
Nuclear transfer
Cloning by nuclear transfer is not itself novel.  The technique was first reported in frogs in 1953 and has been
used widely since in amphibians to study early development.  This work showed that the first few cell divisions
after fertilisation produce cells that are totipotent (i.e. they can develop into all of the cell types that make up the
whole animal).  As the embryo develops further, the cells  lose this property and the success of nuclear transfer
rapidly declines.  Some nuclear transfer experiments using cells from adult frogs produced viable embryos, but
these never developed beyond the tadpole stage.
Nuclear transfer in mammals proved to be more difficult. The cloning of mice using nuclei from very
early embryos was reported in 1977 but this work was not repeatable and interest among developmental
biologists waned.  Research on nuclear transfer in cattle continued, stimulated by the potentially large commercial
benefits of multiplying elite embryos.  Artificial insemination allows each bull to have thousands of offspring but
each cow can only produce 5 or 6 calves in a lifetime.   Multiple ovulation embryo transfer (MOET) and cloning
by embryo splitting have been used to partially redress this imbalance,  but these techniques have limited potential
for further development.  By contrast, nuclear transfer has, at least in principle, the ability to produce an unlimited
number of identical animals.
By the middle of the 1980's several research groups from around the world had produced cloned sheep
and cattle by transferring nuclei directly from early embryos.   In 1985 Steen Willesden in the US had produce
live calves  by nuclear transfer from embryos that had progressed to the 64- and 128-cell stage and this was the
first suggestion that nuclear transfer in mammals  was possible from at least partially differentiated cells.
In the early 1980's the then Animal Breeding Research Organisation initiated a programme designed to
produce transgenic sheep and cattle that would secrete human proteins in their milk. Using the beta- lactoglobulin
promoter, John Clark and colleagues were able to direct expression of the transgene to the mammary gland. This
success led to the setting up in 1987 of PPL Therapeutics and in 1989 the  production of  Tracy, a transgenic
sheep that secreted 35 g of a human protein- alpha-1-antitrypsin- in her milk.  Over the same period other groups
had developed other transgenic livestock, including genetically modified pigs for use as sources of organs for
transplantation to human patients.
At this time the only way of producing transgenic livestock was by pro-nuclear injection.  This procedure
involves the introduction of 200-300 copies of the transgene into a recently fertilised egg which is then implanted
in a surrogate mother. Only 2-3% of eggs give rise to transgenic offspring and only a small proportion of these
express the added gene at sufficiently high levels to be of commercial interest.  It was also only possible to add
genes.
If animals can be derived from cells in culture, then it is possible to carry out much more specific genetic
modifications, including the removal or substitution of specific genes.  This has been achieved in mice using
embryo stem (ES) cells but to date no one has yet succeeded in obtaining ES cells from cattle, sheep or pigs. After
learning of Willesden’s  success,  Ian Wilmut thought that nuclear transfer might provide an alternative.
The major  breakthrough came in 1995 when Keith Campbell, Ian Wilmut and colleagues  produced live
lambs - Megan and Morag - by nuclear transfer from cells from early embryos that had been cultured for several
months in the laboratory.   The key element in this success was the induction of quiescence in the donor cells.
However, at this stage they did not know if they had also stumbled on a particular amenable cell type simply  by
chance.
Additional experiments were performed to test if successful nuclear transfer technique was restricted to
 embryo-derived cells or could be carried out with a wider range of cell types.  Nuclear transfer was carried out
from  embryo-derived cells, foetal fibroblasts and - in collaboration with PPL Therapeutics - cells from an adult
ewe.  Four lambs were born from embryo cells, two from the foetal cells and one, subsequently named Dolly,
from an adult cell.  Their identity was confirmed by DNA testing and the results published in Nature on 27
February 1997.
Practical applications of cloning
The ability (via nuclear transfer)  to derive live animals from cultured cells provides an alternative way of 
producing  transgenic farm animals.  Moreover, the ability to manipulate many millions of cells at once opens
up the possibility of much more specific genetic modifications,  including the deletion or substitution of specific
genes or the introduction of the single letter changes in the whole of the genetic code that are characteristic  of
many human genetic diseases.
human therapeutic proteins
Human proteins are in great demand for the treatment of a variety of diseases. Whereas some can be purified from
blood,  this is expensive and runs the risk of contamination by AIDS or hepatitis C.  Proteins can be produced
in human cell culture but costs are very high and output small.  Much larger quantities can be produced in bacteria
or yeast but the proteins produced can be difficult to purify and they lack the appropriate post-translational
modifications that are needed for efficacy in vivo.
By contrast, human proteins that have appropriate post-translational modifications can be produced in
 the milk of transgenic sheep, goats and cattle.  Output can be as high as 40 g per litre of milk and costs are
relatively low.  PPL Therapeutics, one of the leaders in this field, recently announced that alpha-1-antitrypsin
produced from a transgenic flock is now being used to treat cystic fibrosis patients in phase 2 clinical trials. In
the US, Genzyme Transgenics have focussed on goats and their lead product, tissue plasminogen activator, is also
in clinical trials. 
An immediate advantage of producing transgenic animals by nuclear transfer is  that it uses less than half
of the  experimental animals than does pronuclear injection. It is also possible  to specify the sex of the offspring
and thereby substantially reduce the time taken to generate a production flock. PPL and the Roslin Institute have
already used this approach to produce Polly and Molly, two transgenic sheep that secrete the human blood clotting
factor IX in their milk.
At present such transgenic animals produce a human protein in addition to the normal complement of
milk proteins. This restricts yield and with some proteins there would be a major advantage in removing one or
more of the endogenous milk proteins.  This is the case with serum albumin where the total demand for treatment
of burns and other trauma is estimated at over 600 tonnes each year. In this case production would be in cattle
and the aim would be to replace the bovine albumin gene with its human equivalent.
nutraceuticals
There are a number of potential opportunities for altering the nutritional content of milk.  For example, cow’s
milk is ideal for calves but not for premature infants.  Gene targeting using nuclear transfer will allow milk to be
produced in which one or more of the normal cow’s proteins have been replaced by human proteins,  thereby
improving its nutritional quality for these special ‘consumers’.  Other people have a immune response to specific
proteins in milk or are intolerant of lactose and gene targeting  would allow the creation of herds of cows that
produced milk lacking the problem  components.
xenotransplantation
Over the past 20 years transplantation of hearts and kidneys has become almost routine.  There is an  shortage
of suitable organs for transplant (about 5000 each year in the UK) and many patients have to suffer prolonged
dialysis and/or die as a result. Transgenic pigs are being developed as sources of organs to meet the shortfall.
  The pigs produced so far have an added human protein such as compliment inhibitory factor that coats the pig
tissues and is intended to prevent immediate rejection of the transplanted heart or kidney.
The ability to remove genes could have a major impact on the success of such xenotransplants. 
Surprisingly, most of the antibodies in our blood that would the react against a pig organs recognise a single
carbohydrate linkage, galactose alpha (1,3) galactose.  This sugar residue does not appear to be functionally
important because it is not present in  humans and monkeys.  Elimination of the glycosyltransferase responsible
for attaching this sugar residue by targeting the relevant gene in pigs is therefore expected to greatly reduce
hyperacute rejection of transplanted organs.
animal models of disease
Mice in which specific mutations have been deliberately introduced have often proved very useful as models for
studying  human genetic diseases.  In some cases, differences between mice and humans means that the effects
of the introduced  mutation are not the same as in the human genetic disease.  This is the case for the cystic
fibrosis mutation, where differences in chloride channel mean that the knock out experiment in mice has little
effect on  lung physiology.
Nuclear transfer will extend the range of species in which gene targeting will be possible and thereby
provide better models to  test treatments for  human diseases.  Lung physiology in sheep and humans is very
similar and the gene targeting to introduce the cystic fibrosis mutation in sheep would be expected to produce a
similar phenotype in homozygous animals to that in man.  The deliberate creation of a genetic disease in a large
animal raise public concerns and the ethical justification of creation of such a model would need to be well argued.
cell therapy
Intact cells are already  used to treat patients suffering from a number of diseases, including leukemia and
Parkinson’s disease.  In most cases these cells have to be obtained from close relatives to avoid problems of
immune rejection.
The fact that Dolly was cloned from a cell taken from an adult ewe shows that even differentiated cells
can be ‘reprogrammed’ into all the cell types that make up an intact animal. The only way that we can perform
this dedifferentiation step now  is by ‘incubating’ cells  in the cytoplasm of an unfertilised egg but when we know
more about the mechanisms involved, then it may be possible that human  cells can be reprogrammed without
the use of a human egg.  This would allow the patient’s  own cells to be used in cell  therapies, thereby avoiding
the time, expensive and uncertainty  of  tissue matching.  Cells would removed from the patient, converted into
the desired cell type in the laboratory and then reintroduced into same patient for treatment. 
cloning in farm animal production
In addition to providing a route to gene targeting in livestock, nuclear transfer could  be used to deliver what is
the popular image of cloning:  that is the production of,  at least  in principle, unlimited numbers of genetically
identical animals.
There are major practical hurdles to overcome before this could be a routine procedure in livestock
production.  We first need to show the techniques can be used in cattle and pigs since it is probably only in these
species that the benefits are likely to justify the cost.  Non-surgical means would be needed for embryo transfer
and success rates would have to be dramatically improved. Previous experience with new technologies such as
artificial insemination and multiple ovulation embryo transfer suggest that it may be 10-20 years before this could
be possible
Nevertheless, the main advantage of cloning would not be in selection programmes but in the more rapid
dissemination of genetic progress from elite herds to the commercial farmer.   At present this is achieved through
artificial insemination - which supplies only half the genes- and by limited use of embryo transfer. This process
is not that efficient and in dairy cattle, the performance of the average cow  is probably some 10 years behind
 the best.   With cloning, it would be possible to remove this difference.  Farmers who could afford it would
receive embryos that would be clones of the most productive cows of elite herds and thereby lift the performance
of their herds to that of the very best within one generation.   This  would be a one-off gain, since from then on
the rate of genetic progress would return to that of the elite herds.
In this scenario, breeding companies would sell cloned embryos in much the same way as they now sell
semen.  Farmers would choose cloned embryos for high merit beef bulls or dairy cows from catalogues that
described the genetic merit for a series of economically important traits, including fertility, health and longevity.
 The cloned embryo would be delivered to the farm much in the same way as semen straws are today, perhaps
from breeders overseas.
A major risk would be loss of genetic diversity but this could be avoided by systems that ensured that
breeding companies produced a limited number of clones of each genotype and restricted the number of each of
the clones that could be sold to any one producer.   Although the herds of some producers might consist entirely
of cloned animals, the fact that they were clones of different elite animals may actually increase genetic diversity
on some farms. 
genetic conservation
Although cloning is associated in most people’s minds with a loss of genetic diversity,  the techniques that were
used to produce Dolly will also provide new approaches to genetic conservation.   With increasing commercial
pressures, many indigenous breeds  adapted to local conditions are under threat from imported  breeds that are
being reared in intensive farming systems.  The local breeds may contain valuable genes that confer heat tolerance
or disease resistance and there is an urgent need to prevent their extinction.  Current methods of conservation
involve storage of frozen semen or embryos but are time consuming and  costly. As a consequence, the future of
only a small proportion of endangered breeds is being addressed.
The new techniques developed at Roslin may  provide much simpler and  more effective means of
conserving breeds.   Blood samples, skin biopsies or even hair follicles might be suitable sources of cells that
could be grown briefly in the laboratory and then frozen in liquid nitrogen for long term storage or transfer to
other endangered populations.
To some these applications seem much less glamorous than the prospect of the cloning of human
beings. In reality, they have the potential to provide radical new treatments for a wide variety of serious
diseases that affect many millions of people world-wide.  By contrast, the cloning of human beings- if and
when it happens- is likely to remain a marginal activity with little impact on society beyond the immediate
participants.
Further information on cloning, including references to work cited, is  available on the Institute’s web site on
www.ri.bbsrc.ac.uk
